11/12/2024 | Press release | Distributed by Public on 11/12/2024 15:40
FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Kumar Dinesh M. C/O ASTRANA HEALTH, INC. 1668 S. GARFIELD AVENUE, 2ND FLOOR ALHAMBRA, CA 91801 |
See remarks |
/s/ Kathy Diep, as Attorney-in-Fact | 11/12/2024 |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest subject to the achievement of certain performance goals, provided the Reporting Person is still employed with the Issuer on the date of vesting. |
(2) | Includes 214,370 shares of restricted stock, which will vest as follows (in each case subject to continuous employment with the Issuer): (i) 85,130 shares, which will vest in three equal annual installments beginning on January 23, 2025 (ii) 9,790 shares, which will vest in three equal semi-annual installments beginning on January 1, 2025; and (iii) grants of 16,316, 16,316, 13,053, 6,527 and 67,238 shares, each of which will vest subject to the achievement of certain performance goals. |
Remarks: Chief Medical Officer of Astrana Health Enablement of Nevada, Inc., a wholly owned subsidiary of Astrana Health, Inc. |